Right Drug Dose Now Act of 2025
- Bill Number
- H.R. 2471
- Origin Chamber
- House
- Congress
- 119th Congress, Session 1
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2025-03-27: Referred to the House Committee on Energy and Commerce.
- Last Updated
- 2025-04-07T13:44:44Z
AI-Generated Summary
Purpose of the Legislation
The "Right Drug Dose Now Act of 2025" aims to reduce adverse drug events (unwanted side effects from medications) by incorporating recent advances in pharmacogenomics—the study of how a person's genes affect their response to drugs. It updates existing federal plans and tools to promote personalized medicine, improves electronic health records (EHRs) to better handle genetic testing data, and enhances education and reporting for safer prescribing.
Key Provisions
- Updating the National Action Plan for Adverse Drug Event Prevention (Section 3):
- Requires the Secretary of Health and Human Services (HHS) to submit a report to Congress within 180 days of enactment on the progress of the current plan.
- Directs HHS to convene a federal interagency committee to revise the plan, focusing on:
- Advances in drug-gene interactions (how genes influence drug effects, including multiple drugs and genes), clinical results, health care costs, and cheaper genetic testing.
- The role of pharmacogenetic testing (genetic tests to guide drug choices) combined with clinical decision tools as a prevention method.
- Improvements to federal systems for monitoring adverse drug events, including better detection of genetic links.
- Education for Health Care Professionals on Adverse Drug Events and Pharmacogenomic Testing (Section 4):
- Mandates HHS to issue guidance for providers (e.g., doctors, pharmacists, nurses, genetic specialists, educators) covering:
- How pharmacogenomic testing can prevent bad reactions to drugs.
- Use of testing, drug interaction alerts, when to consult genetics experts, and federal care standards for patients with gene variants affecting drug processing.
- Encouraging appropriate use of testing in patient care plans.
- Roles of genetics specialists and integrating pharmacogenomics into overall medication management.
- Importance of including pharmacogenomic data when reporting adverse events to the FDA's system.
- Improving Electronic Health Record (EHR) Systems for Pharmacogenomic Information (Section 5):
- Requires guidance for providers and leaders on EHR technologies (including e-prescribing and pharmacy checks) to automatically alert users before completing a medication order about:
- When pharmacogenomic testing is recommended based on drug labels or expert guidelines.
- Drug-gene or drug-drug-gene risks from a patient's medications, allergies, and test results.
- Directs HHS to issue and update (at least every six months) guidance on drug-gene alerts in EHRs, incorporating new drug labels and guidelines.
- Encourages EHR systems that allow direct reporting of adverse events to the FDA.
- Mandates updates to the FDA Adverse Event Reporting System (FAERS) to include optional tools for noting genetic interactions and direct EHR integration; develops patient-friendly mobile reporting options; and requires a progress report to Congress within one year.
- Requires a Government Accountability Office (GAO) study within 180 days on how the FDA can add and update drug-gene information on drug labels, with recommendations to Congress.
- Directs HHS to report to Congress within 180 days on further EHR improvements needed for real-world evidence in pharmacogenomics, including capturing details on tests and labs used.
Significant Changes to Existing Law
- Builds on the existing National Action Plan for Adverse Drug Event Prevention by mandating its update to explicitly include pharmacogenomic advances, which were not previously emphasized.
- Enhances the FDA's FAERS by adding genetic reporting features and EHR integration, streamlining data collection without creating new systems.
- Introduces routine guidance and biannual updates for EHR alerts and professional education, promoting proactive use of genetic data in prescribing— a shift toward integrating precision medicine into routine care.
- No fundamental restructuring of laws like the Federal Food, Drug, and Cosmetic Act, but adds requirements for reports, studies, and coordination to evolve monitoring and certification criteria for health IT.
Potential Impacts
- On Government Agencies: Increases workload for HHS and FDA in reporting, guidance issuance, system updates, and interagency coordination; GAO conducts a targeted study. Could improve efficiency in adverse event tracking through better data integration.
- On Citizens: May reduce harmful drug reactions by enabling gene-based prescribing, leading to safer, more effective treatments and lower health care costs from fewer hospitalizations. Patients gain easier ways to report issues via mobile apps.
- On International Relations: No direct impacts mentioned; focuses on domestic health systems and federal operations.
Main Stakeholders Affected
- Health Care Professionals and Institutions: Doctors, pharmacists, nurses, geneticists, educators, and administrators who must adopt new guidance, use updated EHR alerts, and incorporate pharmacogenomic testing into practice.
- Patients and the Public: Individuals receiving medications, particularly those with genetic risks for adverse reactions, benefiting from personalized care and simplified reporting.
- Government Entities: HHS, FDA (for system updates and labels), interagency committees, and Congress (receiving reports and recommendations).
- Technology and Pharma Sectors: EHR developers (e.g., for certification and alerts) and drug manufacturers (impacted by label updates on gene interactions).
Notable Legal, Constitutional, or Political Implications
- Legal: Strengthens evidence-based standards for care by referencing drug labels and peer-reviewed guidelines, potentially reducing liability for providers through clearer federal guidance on genetic testing. Encourages voluntary reporting without mandating tests, respecting patient privacy under existing laws like HIPAA (Health Insurance Portability and Accountability Act, which protects health data).
- Constitutional: No apparent conflicts; aligns with Congress's authority to regulate public health and interstate commerce in drugs and medical devices.
- Political: Bipartisan sponsorship (by Reps. Swalwell and Crenshaw) suggests broad support for advancing precision medicine. Could influence future health policy by prioritizing pharmacogenomics in federal planning, but implementation depends on agency resources and may face challenges in adoption by private health systems.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Cosponsors (1)
Recent Actions
- 2025-03-27: Referred to the House Committee on Energy and Commerce.
- 2025-03-27: Introduced in House
- 2025-03-27: Introduced in House
Bill Versions
- Right Drug Dose Now Act of 2025 — issued 2025-03-27 — PDF (8 pages)